Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial.

Mansoor LE, Yende-Zuma N, Baxter C, Mngadi KT, Dawood H, Gengiah TN, Samsunder N, Schwartz JL, Doncel GF, Abdool Karim Q.

J Int AIDS Soc. 2019 Sep;22(9):e25381. doi: 10.1002/jia2.25381.

2.

Long-term adherence to antiretroviral therapy in a South African adult patient cohort: a retrospective study.

Moosa A, Gengiah TN, Lewis L, Naidoo K.

BMC Infect Dis. 2019 Sep 5;19(1):775. doi: 10.1186/s12879-019-4410-8.

3.

Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART.

Maharaj B, Gengiah TN, Yende-Zuma N, Gengiah S, Naidoo A, Naidoo K.

Int J Tuberc Lung Dis. 2017 May 1;21(5):537-543. doi: 10.5588/ijtld.16.0775.

4.

Assessing Adherence to Antiretroviral Therapy in a Rural Paediatric Cohort in KwaZulu-Natal, South Africa.

Smith C, Gengiah TN, Yende-Zuma N, Upfold M, Naidoo K.

AIDS Behav. 2016 Nov;20(11):2729-2738.

5.

Tenofovir Gel to Prevent HSV-2 Infection.

Abdool Karim SS, Abdool Karim Q, Gengiah TN.

N Engl J Med. 2015 Nov 12;373(20):1980-1. doi: 10.1056/NEJMc1511338. No abstract available.

PMID:
26559584
6.

Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.

Abdool Karim SS, Abdool Karim Q, Kharsany AB, Baxter C, Grobler AC, Werner L, Kashuba A, Mansoor LE, Samsunder N, Mindel A, Gengiah TN; CAPRISA 004 Trial Group.

N Engl J Med. 2015 Aug 6;373(6):530-9. doi: 10.1056/NEJMoa1410649.

7.

Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.

Kashuba AD, Gengiah TN, Werner L, Yang KH, White NR, Karim QA, Abdool Karim SS.

J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):264-9. doi: 10.1097/QAI.0000000000000607.

8.

A qualitative study of patient motivation to adhere to combination antiretroviral therapy in South Africa.

van Loggerenberg F, Gray D, Gengiah S, Kunene P, Gengiah TN, Naidoo K, Grant AD; CAPRISA 058 Study Team.

AIDS Patient Care STDS. 2015 May;29(5):299-306. doi: 10.1089/apc.2014.0293. Epub 2015 Feb 18.

9.

Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.

Mansoor LE, Abdool Karim Q, Mngadi KT, Dlamini S, Montague C, Nkomonde N, Mvandaba N, Baxter C, Gengiah TN, Samsunder N, Dawood H, Grobler A, Frohlich JA, Abdool Karim SS.

Trials. 2014 Dec 19;15:496. doi: 10.1186/1745-6215-15-496.

10.

Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment.

Gengiah TN, Botha JH, Yende-Zuma N, Naidoo K, Abdool Karim SS.

Antivir Ther. 2015;20(3):297-306. doi: 10.3851/IMP2877. Epub 2015 Oct 15.

PMID:
25318122
11.

Low rifampicin concentrations in tuberculosis patients with HIV infection.

Gengiah TN, Botha JH, Soowamber D, Naidoo K, Abdool Karim SS.

J Infect Dev Ctries. 2014 Aug 13;8(8):987-93. doi: 10.3855/jidc.4696.

12.

Individualised motivational counselling to enhance adherence to antiretroviral therapy is not superior to didactic counselling in South African patients: findings of the CAPRISA 058 randomised controlled trial.

van Loggerenberg F, Grant AD, Naidoo K, Murrman M, Gengiah S, Gengiah TN, Fielding K, Abdool Karim SS.

AIDS Behav. 2015 Jan;19(1):145-56. doi: 10.1007/s10461-014-0763-6.

13.

Monitoring microbicide gel use with real-time notification of the container's opening events: results of the CAPRISA Wisebag study.

Gengiah TN, Upfold M, Naidoo A, Mansoor LE, Feldblum PJ, Abdool Karim Q, Abdool Karim SS.

AIDS Behav. 2014 May;18(5):833-40. doi: 10.1007/s10461-014-0750-y.

14.

Measuring adherence by visual inspection of returned empty gel applicators in the CAPRISA 004 microbicide trial.

Gengiah TN, Mansoor LE, Upfold M, Naidoo A, Yende-Zuma N, Kashuba AD, Karim QA, Karim SS.

AIDS Behav. 2014 May;18(5):820-5. doi: 10.1007/s10461-014-0749-4.

15.

Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial.

Naidoo A, Naidoo K, Yende-Zuma N, Gengiah TN, Padayatchi N, Gray AL, Bamber S, Nair G, Karim SS.

Antivir Ther. 2014;19(2):161-9. doi: 10.3851/IMP2701. Epub 2013 Oct 31.

16.

Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.

Gengiah TN, Moosa A, Naidoo A, Mansoor LE.

Int J Clin Pharm. 2014 Feb;36(1):70-85. doi: 10.1007/s11096-013-9861-1. Epub 2013 Oct 16. Review.

17.

Implementing microbicides in low-income countries.

Gengiah TN, Abdool Karim Q.

Best Pract Res Clin Obstet Gynaecol. 2012 Aug;26(4):495-501. doi: 10.1016/j.bpobgyn.2012.02.004. Epub 2012 Apr 11.

18.

A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection.

Gengiah TN, Baxter C, Mansoor LE, Kharsany AB, Abdool Karim SS.

Expert Opin Investig Drugs. 2012 May;21(5):695-715. doi: 10.1517/13543784.2012.667072. Epub 2012 Mar 7. Review.

19.

The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.

Gengiah TN, Holford NH, Botha JH, Gray AL, Naidoo K, Abdool Karim SS.

Eur J Clin Pharmacol. 2012 May;68(5):689-95. doi: 10.1007/s00228-011-1166-5. Epub 2011 Nov 23.

20.

Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.

Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende N, Mansoor LE, Mlisana KP, Maarschalk S, Arulappan N, Grobler A, Sibeko S, Omar Z, Gengiah TN, Mlotshwa M, Samsunder N, Karim SS.

Trials. 2011 Mar 7;12:67. doi: 10.1186/1745-6215-12-67.

21.

Initiating antiretrovirals during tuberculosis treatment: a drug safety review.

Gengiah TN, Gray AL, Naidoo K, Karim QA.

Expert Opin Drug Saf. 2011 Jul;10(4):559-74. doi: 10.1517/14740338.2011.546783. Epub 2011 Jan 5. Review.

22.

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group.

Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19. Erratum in: Science. 2011 Jul 29;333(6042):524.

23.

Supplemental Content

Loading ...
Support Center